CompletedPHASE1, PHASE2NCT04413344

Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease

Studying Early-onset autosomal dominant Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Kyoto University
Principal Investigator
Haruhisa Inoue, MD, PhD
Kyoto University
Intervention
Bromocriptine Mesilate(drug)
Enrollment
8 target
Eligibility
20 years · All sexes
Timeline
20202021

Study locations (8)

Collaborators

Mie University · Osaka University · Tokushima University · Tokyo Metropolitan Institute for Geriatrics and Gerontology · Asakayama Hospital · Kawasaki Medical School Hospital · Nagoya City University Hospital · Time Therapeutics, Inc. · Towa Pharmaceutical Co.,Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04413344 on ClinicalTrials.gov

Other trials for Early-onset autosomal dominant Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for Early-onset autosomal dominant Alzheimer disease

← Back to all trials